Panobacumab
Based on 1 Customer Validation
Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.24%
- CAS. Nr.: 885053-97-4
- Molecular Weight:172.5 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Human IgM kappa
Pseudomonas aeruginosa
Panobacumab (KBPA101) strongly binds to 18 of 20 clinical O11 isolates, functional avidity of KBPA101 to O11 LPS determined by inhibition ELISA is 5.81×107 M-1± 2.8×107 M-1[1].
Panobacumab (KBPA101) (0.0001-100 ng/mL; 2 h) specifically mediates complement-dependent opsonophagocytosis of P. aeruginosa serotype O11 with an IC50 of 0.16 ng/mL[1].
Panobacumab (KBPA101) (0.1-10 ng/mL) shows direct complement-dependent killing of P. aeruginosa serotype O11 cells in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Panobacumab (KBPA101) (0.005-0.4 mg/kg; i.v.; once) protects mice from local lung infection with P. aeruginosa serotype O11 in an acute lung infection model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NMRI mice, murine burn wound model[1]
-
Dosage:1, 2, or 4 mg/kg
-
Administration:Intravenous injection, single dose
-
Result:Significantly reduced mortality compared to untreated control animals administered either immediately or 4 h postchallenge.
-
Animal Model:BALB/c mice, acute lung infection model[1]
-
Dosage:0.005 to 0.4 mg/kg
-
Administration:Intravenous injection, single dose
-
Result:Led to rapid clearance of P. aeruginosa from the lung, completely cleared systemic P. aeruginosa from the spleen, whereas live bacteria were still present in untreated mice at 48 h postchallenge, showed milder macroscopic lung pathology at 6 and 24 h after infection.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgM-kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS. Nr. 885053-97-4
-
Appearance Liquid
-
Molecular Weight 172.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Panobacumab]
-
Synonyms
KBPA101
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Panobacumab Related Classifications
HY-P99214 Related Classifications
Powered by Bioz